Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
9 July 2025
In parallel, smaller studies and case series continue to report on off-label use, adding to our knowledge
10.1038/s41586-020-2732-8 Summary Keywords diabetic kidney disease, ferroptosis, kidney biomarkers, pharmacological intervention, SGLT2 inhibitors Citation He S, Wu Z and Li S (2026) Ferroptosis regulation by SGLT2 inhibitors: mechanisms and clinical benefits in diabetic kidney disease
GIP Medications Metabolic Regulation: GIP medications enhance insulin secretion and may improve overall metabolic health
It is recommended that patients taking Trulicity or another GLP-1 agonist, weigh the benefits of using the medication against the potential risks, particularly when using the drug for a non-diabetic condition such as weight loss
The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language
